Photocure initiates arbitration against Asieris over unpaid USD 4.4 million milestone paymentPUBT·Jul 23 at 08:38 AM688176+1.70%
The three major A-share indices turned positive collectively, innovative drugs rebounded, the Hang Seng Index rose nearly 3%, JD.com increased by over 7%, while crude oil and the shipping index plummetedWallstreetcn·Mar 5 at 08:40 PM513120+0.70%KJD+0.42%
The three major A-share indices collectively closed higher, with over 4,200 stocks in the entire market in the green36Kr·Mar 6 at 01:08 AM399001+2.21%600319+0.18%
Asieris Soars as China Approves World’s First Non-Invasive Treatment for Cervical Precancerous LesionsYicai·Mar 4 at 04:36 AM688176+1.70%
CEVIRA, a non-invasive therapy for cervical precancerous lesions, approved in China by Asieris Pharmaceuticals.Unusual Whales·Mar 3 at 03:54 AM688176+1.70%
EMA accepted marketing authorization app for Cevira by Asieris; collaboration with Photocure.Unusual Whales·Feb 27 at 04:06 AM688176+1.70%
Asieris: Data related to the international multicenter Phase III clinical trial of APL-1702 published in the international journal "Med"Zhitong·Oct 10, 2025 at 03:23 AM688176+1.70%
Asieris Pharmaceuticals' director and executive Yang Mingyuan resigns for personal reasonsZhitong·Sep 30, 2025 at 06:07 AM688176+1.70%
Novartis partners with Asieris to bet on cardiovascular asset, with a total transaction amount of up to 5.2 billion USDZhitong·Sep 3, 2025 at 08:42 AMNVS-0.25%688176+1.70%
Asieris Pharmaceuticals released its semi-annual performance, with a net loss attributable to the parent company of 162 million yuanZhitong·Aug 28, 2025 at 06:48 AM688176+1.70%
05:40 ET Asieris Pharmaceuticals Releases 2025 Semi-Annual Report with Sustained Commercial Momentum and Breakthrough Innovation Poised for Launchprnewswire·Aug 28, 2025 at 04:41 AM688176+1.70%
